Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial.
Some people with specific rectal cancers respond completely to immunotherapy alone, potentially avoiding surgery and radiation's significant side effects.
Multimodal treatment with chemotherapy, radiation, and surgery for locally advanced rectal cancer (LARC) is a standard of care (SOC) associated with significant toxicity/morbidity. These durable responses indicate the potential to eliminate the need for current SOC and redefine the curative-intent treatment paradigm with dostarlimab in dMMR/MSI-H LARC.
What the study was
- Study design
- Observational or experimental study
- Population
- Multimodal treatment with chemotherapy, radiation, and surgery for locally advanced rectal cancer (LARC) is a standard of care (SOC) associated with significant toxicity/morbidity.
- Sample size
- 154
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Ann Oncol
Why it surfaced
Observational or experimental study with a PubMed abstract reviewed; the 8/10 score reflects conservative novelty, relevance, design-quality, and population/unmet-need assessment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.